Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma

Autor: Fred S. Gorelick, John W. Kunstman, Charles Cha, Yasheen Gao, Jill Lacy, Xiaojia Guo, Sade´ M. B. Finn, Melinda Wang, Gary V. Desir, Tian-min Chen, Joanna Hu, Melena D. Bellin, Marie E. Robert
Rok vydání: 2021
Předmět:
Male
endocrine system diseases
Physiology
Cancer Treatment
Gastroenterology
Serology
Borderline resectable
Medicine and Health Sciences
Prospective Studies
Renalase
Aged
80 and over
Multidisciplinary
Middle Aged
Prognosis
Tumor Resection
Up-Regulation
Body Fluids
Gene Expression Regulation
Neoplastic
Surgical Oncology
Blood
medicine.anatomical_structure
Oncology
Nephrology
Renal Cancer
Normal pancreas
Medicine
Biomarker (medicine)
Immunohistochemistry
Female
Anatomy
Pancreas
Carcinoma
Pancreatic Ductal
Research Article
Adult
Clinical Oncology
medicine.medical_specialty
Pancreatic ductal adenocarcinoma
Science
Surgical and Invasive Medical Procedures
Endocrine System
Gastroenterology and Hepatology
Blood Plasma
Young Adult
Pancreatic Cancer
Exocrine Glands
Pancreatic cancer
Internal medicine
Gastrointestinal Tumors
Biomarkers
Tumor
medicine
Carcinoma
Humans
Monoamine Oxidase
Survival analysis
Aged
Retrospective Studies
Surgical Resection
business.industry
Cancers and Neoplasms
Biology and Life Sciences
medicine.disease
Survival Analysis
digestive system diseases
Pancreatic Neoplasms
Pancreatitis
Case-Control Studies
Neoplasm Grading
Clinical Medicine
business
Zdroj: PLoS ONE, Vol 16, Iss 9, p e0250539 (2021)
PLoS ONE
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0250539
Popis: Dysregulated expression of the secretory protein renalase can promote pancreatic ductal adenocarcinoma (PDAC) growth in animal models. We characterized renalase expression in premalignant and malignant PDAC tissue and investigated whether plasma renalase levels corresponded to clinical PDAC characteristics. Renalase immunohistochemistry was used to determine the presence and distribution of renalase in normal pancreas, chronic pancreatitis, PDAC precursor lesions, and PDAC tissues. Associations between pretreatment plasma renalase and PDAC clinical status were assessed in patients with varied clinical stages of PDAC and included tumor characteristics, surgical resection in locally advanced/borderline resectable PDAC, and overall survival. Data were retrospectively obtained and correlated using non-parametric analysis. Little to no renalase was detected by histochemistry in the normal pancreatic head in the absence of abdominal trauma. In chronic pancreatitis, renalase immunoreactivity localized to peri-acinar spindle-shaped cells in some samples. It was also widely present in PDAC precursor lesions and PDAC tissue. Among 240 patients with PDAC, elevated plasma renalase levels were associated with worse tumor characteristics, including greater angiolymphatic invasion (80.0% vs. 58.1%, p = 0.012) and greater node positive disease (76.5% vs. 56.5%, p = 0.024). Overall survival was worse in patients with high plasma renalase levels with median follow-up of 27.70 months vs. 65.03 months (p < 0.001). Renalase levels also predicted whether patients with locally advanced/borderline resectable PDAC underwent resection (AUC 0.674; 95%CI 0.42–0.82, p = 0.04). Overall tissue renalase was increased in both premalignant and malignant PDAC tissues compared to normal pancreas. Elevated plasma renalase levels were associated with advanced tumor characteristics, decreased overall survival, and reduced resectability in patients with locally advanced/borderline resectable PDAC. These studies show that renalase levels are increased in premalignant pancreatic tissues and that its levels in plasma correspond to the clinical behavior of PDAC.
Databáze: OpenAIRE
Externí odkaz: